The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
A research team at UCLA has developed a deep learning-powered chemiluminescence vertical flow assay (CL-VFA) that brings ...
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
GlobalData on MSN10h
Boehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback